Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

How is ASCEND funded?

Funding for ASCEND is provided by the British Heart Foundation to cover the administrative and coordination costs of the trial. Aspirin and matching placebo is being provided by Bayer Healthcare AG, and omega-3 fatty acid and matching placebo capsules by Mylan (previously Abbott Laboratories), with some funding from each company to cover drug packaging. ASCEND is co-ordinated by CTSU which is funded by the Medical Research Council, which supports the embedded MRC Population Health Research Unit, as well as by grants from the British Heart Foundation and from Cancer Research UK. Alzheimer's Research UK have provided a grant to measure cognitive function in ASCEND participants. The University of Oxford is acting as the sponsor of this study.